Trevigen acquired by Bio-Techne September 5, 2017

September 5, 2017

Overview

Bio-Techne Corporation’s acquired all the stock of Trevigen Inc. for cash.

Bio-Techne provides high-quality reagents, instruments, custom manufacturing, and testing services to researchers in Life Sciences and Clinical Diagnostics.

Trevigen offers world class cell stress, DNA damage, and physiologic cell culture products, and contract services for the biotech research community.

Significance

The Trevigen products complement Bio-Techne’s current product portfolio and make it easier to reach customers interested in products to better understand cell behavior and genotoxic events on cells.

Having a broader array of products will both serve Trevigen’s customers more efficiently, as well as provide additional channels for Trevigen’s products in the global market.

Crosstree’s Role

Crosstree Capital Partners acted as exclusive financial advisor to Trevigen.

Trevigen acquired by Bio-Techne  September 5, 2017